gilead sciences news - Search News

Gilead, LEO Pharma

Gilead, LEO Pharma partner to develop programs for inflammatory diseases

Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases.

Business Insider · 1m

Gilead, LEO Pharma Enter Strategic Partnership To Accelerate Development Of Oral STAT6 Program

Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule

Bloomberg L.P. · 2h

Gilead, Leo Pharma Form Pact Focused on Inflammatory Diseases

Gilead Sciences and LEO Pharma said they formed a strategic partnership to focus on the potential treatment of patients with inflammatory diseases.

Gilead, Morgan Stanley

Hosted on MSN · 1d

Gilead upgraded by Morgan Stanley on lenacapavir potential

Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. The investment bank said it was "leaning into the bull case," seeing "the potential for upward estimate revisions on lenacapavir for PrEP and further multiple expansion as the company makes progress with its

Business Insider · 1d

Gilead upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for

Investing.com on MSN · 1d

Morgan Stanley upgrades Gilead on HIV treatment growth

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV treatments.

1hon MSN

Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B

Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...

Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

21h

Gilead Sciences Inc. stock outperforms competitors on strong trading day

The stock's rise snapped a five-day losing streak.

FierceBiotech3d

Galapagos splits in 2, laying off 40% of staff, shrinking pipeline and ending Gilead partnership

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

Zacks.com on MSN1d

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

Gilead Sciences Inc. stock outperforms competitors despite losses on the day

This was the stock's fifth consecutive day of losses.

ENDPOINTS NEWS1d

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...

13d

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

Morningstar4d

Gilead Sciences Inc GILD

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Armenian Reporter1d

ORG Partners LLC Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

ORG Partners LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.3% in the 4th quarter, ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Gilead, LEO Pharma

Gilead, Morgan Stanley

Related topics